GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy

Manish R Sharma; Richard L Schilsky

doi:10.1038/nrclinonc.2010.219

GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy

Nat Rev Clin Oncol. 2011 Feb;8(2):70-2. doi: 10.1038/nrclinonc.2010.219.

Authors

Manish R Sharma¹, Richard L Schilsky

Affiliation

¹ Section of Hematology-Oncology, Department of Medicine, Comprehensive Cancer Center, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637-1470, USA.

PMID: 21278772
DOI: 10.1038/nrclinonc.2010.219

Abstract

Randomized phase III trials have established new standards of care for advanced biliary cancer, HER2-positive advanced gastric or gastro-esophageal junction cancer, and preliminarily, for metastatic pancreatic cancer. There is now a validated predictive biomarker to guide use of adjuvant chemotherapy in patients with stage II colon cancer.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / genetics
Chemotherapy, Adjuvant
Gastrointestinal Neoplasms / drug therapy*
Gastrointestinal Neoplasms / genetics
Humans
Standard of Care
Time Factors

Substances

Antineoplastic Agents
Biomarkers, Tumor